Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (NCT04370054)

🧪 Interventions in This Study

• PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (45 Sites)

Showing the first 25 of 45 sites.

• NOW Physical Therapy — Mountain View, California
• Regents of The University of California — Oakland, California
• Clinical and Translational Research Unit (CTRU) — Palo Alto, California
• Lucile Packard Childrens Hospital — Palo Alto, California
• Imaging Clinic at Stanford Medicine Outpatient Center in Redwood City — Redwood City, California
• The Board of Trustees of the Leland Stanford Junior University — Redwood City, California
• UCSF Outpatient Radiology. — San Francisco, California
• UCSF IDS Pharmacy — San Francisco, California
• UCSF lnvestigational Drug Service — San Francisco, California
• UCSF Outpatient Radiology (alternate location) — San Francisco, California
• UCSF Outpatient Radiology — San Francisco, California
• University of California, San Francisco - Clinical Research Center — San Francisco, California
• University of California, San Francisco - Moffitt/Long Inpatient Hematology — San Francisco, California
• University of California, San Francisco - Outpatient Hematology Clinic — San Francisco, California
• Access Sourcecorp Deliverex (off-site storage) — San Jose, California
• Stanford Health Care (hospital and IDS pharmacy) — Stanford, California
• Stanford Health Care — Stanford, California
• Washington Institute for Coagulation — Seattle, Washington
• University of Washington Medical Center - Translational Research Unit (TRU) — Seattle, Washington
• The Alfred Hospital — Melbourne, Victoria
• Universidade Estadual de Campina — Campina,
• Hamilton Health Sciences Corporation — Hamilton, Ontario
• McMaster University Medical Centre - Hamilton Health Sciences — Hamilton, Ontario
• Juravinski Hospital - Hamilton Health Sciences — Hamilton, Ontario
• Hopital Necker — Paris,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hemophilia A

• Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" — Little Rock, Arkansas
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Los Angeles, California
• Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A — Milwaukee, Wisconsin
• A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A — Gainesville, Florida
• A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A — Gilbert, Arizona

Explore by condition: All Hemophilia A clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.